Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kalydeco

- PMLiVE

Vertex calls NHS England ‘outrageous’ as Orkambi talks stall again

Public row about confidential pricing talks drags on

- PMLiVE

Daily Brief: Charity criticises NHSE and Vertex over Orkambi access, Sema scores again, NodThera launched

The latest from pharma, biotech and healthcare

The challenges of making genomics a reality for patients

Collaboration is key

- PMLiVE

The challenges of making genomics a reality for patients today, not tomorrow

Creating transformative medicines

- PMLiVE

Vertex’s two-drug cystic fibrosis treatment cleared in US

FDA approves Symdeko, which combines Kalydeco and tezacaftor

- PMLiVE

Vertex’s Orkambi receives EU green light for licence extension

Becomes first medicine to treat the underlying cause of CF in children

- PMLiVE

Vertex’s tezacaftor/ivacaftor shows lung function boost

The combination therapy is currently under review in Europe and the US

- PMLiVE

Vertex hits sweet spot with triple cystic fibrosis therapy

The new treatment could benefit up to 90% of patients with CF

- PMLiVE

Vertex strikes Italian reimbursement deal for Orkambi

AIFA gives the go-ahead for the cystic fibrosis treatment

- PMLiVE

FDA broadens use of cystic fibrosis drug Kalydeco

Drug now available to more patients in the US

- PMLiVE

Vertex’ cystic fibrosis drug too costly, says NICE

£104,000 per patient price tag is "too high" for the drug’s “modest” short term benefit

- PMLiVE

India denies Vertex patent on cystic fibrosis drug Orkambi

Says treatment is neither innovative or more effective than its predecessor

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links